A Phase 3 interventional study of Olezarsen in Familial Chylomicronemia Syndrome, sponsored by Ionis Pharmaceuticals, Inc.. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Ionis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of olezarsen (formerly known as AKCEA -APOCIII-LRX) in participants with FCS previously treated with volanesorsen.
This is a Phase 3, multi-center, open-label safety study in 24 participants with FCS, previously treated with volanesorsen. The study consists of an 8- week screening period, treatment period up to week 209 and a 13-week follow-up period. Participants enrolled will receive olezarsen every 4 weeks during the 209-week Treatment Period.
Treatment period was extended to allow participants to receive olezarsen for an additional 52 weeks for a total of a 209-week treatment period until the drug may be commercially available in the patient's country, or until the Sponsor discontinues the olezarsen development program, whichever occurs earlier.
Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria
Participants with FCS (clinical or genetic diagnosis) currently on or previously treated with volanesorsen (ISIS 304801)
o Study participants in countries where Waylivra® is commercially approved and available for participants should not be deprived of the treatment option with Waylivra®. Participation in this study for such participants will only be allowed when Waylivra® was discontinued due to AEs
The following concomitant medications will be allowed if dosing regimen is expected to remain constant through the end of the study (occasional or intermittent use of over-the-counter (OTC) medications will be allowed at Investigator's discretion):
Key Exclusion Criteria:
Concomitant medication/procedure restrictions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection for up to 209 weeks.
Drug: Olezarsen
Olezarsen will be administered by SC injection.
Also known as: ISIS 678354, AKCEA-APOCIII-LRx
Proportion of Participants With Decrease in Platelet Count by >30% or >50%, or With Platelet Count Value <50,000/cubic millimeter (mm^3)
Time frame: Baseline to Week 209
Proportion of Participants With Clinical Bleeding Events
Time frame: Baseline to Week 209
Proportion of Participants With Decrease in Estimated Glomerular Filtration Rate (eGFR) by ≥30% or ≥50%
Time frame: Baseline to Week 209
Proportion of Participants With Urine Protein/Creatinine Ratio (UPCR) ≥1000 milligram (mg)/gram (g) or with Urine/Albumin Creatinine Ratio (UACR) ≥500 mg/g
Time frame: Baseline to Week 209
Proportion of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥5 x Upper Limit of Normal (ULN)
Time frame: Baseline to Week 209
Proportion of Participants With ALT or AST ≥3 x ULN and Total Bilirubin > 2 x ULN
Time frame: Baseline to Week 209
Proportion of Participants With Total Bilirubin ≥2 mg/deciliter (dL)
Time frame: Baseline to Week 209
Trough (Pre-Dose) Plasma Concentration of Olezarsen
Time frame: Up to 209 weeks
Post-Treatment Plasma Concentration of Olezarsen
Time frame: Up to 209 weeks
Change and Percent Change From Baseline in Fasting Triglycerides (TG)
Time frame: Baseline to Week 209
Change and Percent Change From Baseline in Fasting Apolipoprotein C-III (APOC-III)
Time frame: Baseline to Week 209
Change and Percent Change From Baseline in Fasting Very Low-Density Lipoprotein (VLDL)-C
Time frame: Baseline to Week 209
Change and Percent Change From Baseline in Fasting Chylomicron-TG
Time frame: Baseline to Week 209
Change and Percent Change From Baseline in Fasting Total Cholesterol (TC)
Time frame: Baseline to Week 209
Change and Percent Change From Baseline in Fasting Non-High-Density Lipoprotein (non-HDL)-C
Time frame: Baseline to Week 209
Change and Percent Change From Baseline in Fasting Low-Density Lipoprotein (LDL)-C
Time frame: Baseline to Week 209
Change and Percent Change From Baseline in Fasting Apoprotein B (apoB)
Time frame: Baseline to Week 209
Change and Percent Change From Baseline in Fasting Apoprotein B48 (apoB48)
Time frame: Baseline to Week 209
Change and Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL)-C
Time frame: Baseline to Week 209
Change and Percent Change From Baseline in Fasting Apoprotein A-1 (ApoA-1)
Time frame: Baseline to Week 209
Event Rate of Acute Pancreatitis
Time frame: Up to 209 weeks
Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Jun 2027, 64 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olezarsen
Familial hyperchylomicronemia syndrome